Hyperfine, Inc. (HYPR) AI Stock Analysis

Hyperfine, Inc., based in Guilford, Connecticut, develops and manufactures magnetic resonance imaging (MRI) products. Founded in 2014, the company aims to make MRI technology more accessible and portable. Its primary product is the Swoop Portable MR imaging system, designed to provide neuroimaging directly at the point of care across various clinical settings. Hyperfine combines proprietary MRI technology with clinical collaboration and research to improve diagnostic speed, accuracy, and patient outcomes in acute care environments.

Hyperfine demonstrated rapid early expansion, growing revenue from $1.5M in FY2021 to $6.8M in FY2022, $11.0M in FY2023, $12.9M in FY2024, and $13.6M in FY2025, representing a 5-year revenue CAGR of 115.2% from FY2020 to FY2025. Gross margin steadily improved from -78.0% in FY2021 to 49.8% in FY2025. Operating margin also improved, narrowing from -4336.1% in FY2021 to -273.4% in FY2025. The company posted annual net income losses of -$64.8M in FY2021, -$73.2M in FY2022, -$44.2M in FY2023, -$40.7M in FY2024, and -$35.6M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 44.8% year-over-year, bringing trailing twelve-month revenue to $16.5M with an operating margin of -216.9%.

As of June 30, 2026, Hyperfine held $43.5M in cash and short-term investments and $13.4M in total debt, resulting in net cash of $30.0M. Shareholders' equity was $36.8M out of $63.0M in total assets, with a debt-to-equity ratio of 0.36 and a current ratio of 6.15. In FY2025, operating cash flow was -$27.9M and free cash flow was -$29.1M, with capital expenditures of $1.2M. Over five years, the company's share count increased 41.9%.

Hyperfine carries a market capitalization of $80.0M and an enterprise value of $55.3M. The stock trades at a price-to-sales multiple of 4.8x and an enterprise value-to-revenue multiple of 3.3x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peer group. Its price-to-book ratio is 2.3x. In the market, HYPR shares fell 46.8% over the past year and 92.4% over five years, underperforming the S&P 500, which gained 16.8% and 83.0% over the same respective periods.

Wall Street coverage includes 3 Strong Buy ratings and zero Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $2.03, representing an upside of 169.3% from the last close of $0.76. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.34 and revenue of $20.2M. For the following fiscal year, one analyst estimates revenue of $26.2M, representing 29.7% growth, with EPS of -$0.32. Hyperfine beat EPS estimates once in the last 4 quarters, with its next earnings date scheduled for November 9, 2026.

This page is an AI-written research summary of Hyperfine, Inc. (HYPR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HYPR income statement, HYPR balance sheet, HYPR key metrics, HYPR analyst forecast, HYPR chart. See the HYPR stock overview for the latest quote and news.